RepliCel Life Sciences Cash/Share
What is the Cash/Share of RepliCel Life Sciences?
The Cash/Share of RepliCel Life Sciences, Inc. is 0.00
What is the definition of Cash/Share?
Cash per share is a company’s cash on hand divided by the company’s shares outstanding.
mrq (most recent quarter)
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
Cash/Share of companies in the Health Care sector on TSXV compared to RepliCel Life Sciences
What does RepliCel Life Sciences do?
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
Companies with cash/share similar to RepliCel Life Sciences
- Perk Labs has Cash/Share of 0.00
- Pipeline Engineering has Cash/Share of 0.00
- Enservco Corp has Cash/Share of 0.00
- Canada Cobalt Works has Cash/Share of 0.00
- Sirona Biochem has Cash/Share of 0.00
- The Barkby PLC has Cash/Share of 0.00
- RepliCel Life Sciences has Cash/Share of 0.00
- Legacy Iron Ore has Cash/Share of 0.00
- Fatfish Blockchain has Cash/Share of 0.00
- North Arrow Minerals has Cash/Share of 0.00
- Logiq Inc has Cash/Share of 0.00
- Minaurum Gold has Cash/Share of 0.00
- Namibia Critical Metals has Cash/Share of 0.00